Antibody Drug Conjugates: Technologies and Global Markets - Product Image

Antibody Drug Conjugates: Technologies and Global Markets

  • ID: 4330568
  • Report
  • Region: Global
  • 132 Pages
  • BCC Research
15%OFF
until Jun 30th 2018
1 of 6
The Global Market for Antibody Drug Conjugates Was Valued at $1.3 Billion in 2016. the Market Should Reach $4.2 Billion By 2021, Growing at a CAGR of 25.5% from 2016 to 2021

FEATURED COMPANIES

  • Genentech Inc.
  • Seattle Genetics Inc
  • MORE

Antibody drug conjugate (ADC) technology is a relatively new technology and is continuously evolving due to various factors such as technological advances, recognition of appropriate target antigens, success of monoclonal antibodies (mAbs) and increasing demand for biologics/biotherapeutics. Advances in targeting antibodies, potent payloads and drug-linker technologies that facilitate improved ADC stability, potency and targeting efficiency have led to the development of two commercially viable ADCs. The goal in conducting this study is to provide an overview of the current and future characteristics of the global market for antibody drug conjugates.

This report explores present and future strategies within the antibody drug conjugates market, which includes, by type of payload (cytotoxic agent), by type of monoclonal antibodies and by type of linker. The inception of the market, and its demands and restraints are discussed in this report. Classification,comparisons and usage of ADC products are also presented in this report.

A detailed analysis of the structure of the antibody drug conjugate industry has been conducted. Revenues are broken down by region, with sales estimated for the five-year period from 2016 through 2021. Applications of antibody drug conjugates and significant patents and their allotments in each category discussed.

Reasons for Doing This Study

Advancements in research have changed the way many diseases are treated. ADCs represent an innovative class of drugs that are mainly developed by conjugating already-developed or marketed small molecules and biologics. ADCs have shown great potential in cancer therapy. ADC products are becoming an important part of the biomedical industry and have the potential to replace conventional treatment options.

R&D spending, along with increasing competition, patent expiries and new technologies are providing a new direction to the market. Advancements, new product launches and changing lifestyles are expected to influence the future growth of the market. This study looks at the majority of the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type company in light of the new technologies, growing competition and changing customer needs.

Scope of Report

Antibody drug conjugates are mainly used to treat cancer and are safer and more effective than many other cancer therapies. This report focuses on the global market for antibody drug conjugate products and provides an updated review, including their basic design and application in various areas of the biomedical sciences. The report covers three main areas of application, breast cancer, lymphoma and other cancers, including acute myeloid leukemia. The scope of this study includes the current market for ADCs. The report also discusses regulatory aspects, current and developing technologies, market projections and market shares. An analysis of clinical trials, innovations and opportunities and the latest trends in ADC market are also discussed in the report.

Also included in the report is an analysis of relevant patents and profiles of companies that lead the antibody drug conjugate product market. Seattle Genetics Inc., Takeda Pharmaceuticals Co. Ltd. and Genentech Inc. are the major players in the market for ADCs at present.

Sales data for the global and regional markets were corroborated for the present and forecasted values via statistical analysis, and sales are broken down geographically into North America, Europe, AsiaPacific and the emerging markets. The application of ADCs in various types of cancer is discussed from both a commercial perspective and that of a research and development (R&D) perspective.

The report only covers antibody drug conjugates in which an antibody is conjugated with small-molecule cytotoxins (payload) through a linker. ADCs are a form of antibody conjugates. Other forms of antibody conjugates such as radioisotope conjugated with an antibody are beyond the scope of this report. The study also does not cover mAbs that do not contain a linker and cytotoxic agent and, thus, do not constitute an ADC.

READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Genentech Inc.
  • Seattle Genetics Inc
  • MORE

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Definitions
  • Components of ADCs
  • How ADCs Work
  • Historical Perspective
  • Advantages of ADCs
  • Approved ADCs
  • Mylotarg (Gemtuzumab Ozogamicin)
  • Adcetris (Brentuximab Vedotin)
  • Kadcyla (Trastuzumab-DM1)
  • Antibody Drug Conjugation Technologies
  • Key ADC Targets
  • CD19
  • CD20
  • CD22
  • CD25
  • CD30
  • CD33
  • CD40
  • CD56
  • CD74
  • CD79a and CD79b
  • CD138 (Syndecan-1)
  • CEACAM (Carcinoembryonic Antigen-Related Cell Adhesion Molecule)
  • EGFR (Epidermal Growth Factor Receptor/ERBB1)
  • EGP-1 (Epithelial Glycoprotein-1 Antigen)
  • GPNMB
  • HER2 (Human Epidermal Growth Factor Receptor)
  • LIV-1
  • Mesothelin
  • Nectin-4
  • Prostate-Specific Membrane Antigen (PSMA)
  • SLITRK6
  • VEGF (Vascular Endothelial Growth Factor)
  • Types of Monoclonal Antibodies
  • Types of Payloads (Cytotoxic Agents)
  • Types of Linkers
  • Conjugation Methods
  • Conventional Conjugation Method
  • Site-Specific Conjugation

Chapter 4: Market Breakdown by Technology Type

  • Market for ADCs by Type of Payload
  • Market Overview
  • Market Revenues
  • Market for ADCs by Type of Monoclonal Antibody
  • Market Overview
  • Market Revenues
  • Market for ADCs by Type of Linker
  • Market Overview
  • Market Revenues

Chapter 5: Market Breakdown by Application

  • Global Market for the Application of ADCs in Treating Various Types of Cancers
  • Market Share
  • Breast Cancer
  • Lymphoma
  • Other Types of Cancer

Chapter 6: Industry Structure

  • Market Leaders
  • Market Share

Chapter 7: Market Breakdown by Region

  • Market Overview
  • Market Revenues
  • Market for ADCs by Target Antigen
  • Market for CD-30 Targeting ADCs
  • Market for HER2 Targeting ADCs
  • Market for Other Antigen Targeting ADCs

Chapter 8: Patent Review/New Developments

  • Patent Analysis
  • Patents by Year
  • Patents by Company
  • Patents by Country
  • Patents by Assignee
  • New Developments
  • CMC-544
  • CDX-011
  • RG7596 (Polatuzumab Vedotin)
  • RG7593 (Pinatuzumab Vedotin)
  • PSMA ADC
  • IMGN853 (Mirvetuximab Soravtansine)
  • BT-062
  • Regulatory Issues
  • Regulatory History of Approved ADCs
  • Regulatory Exclusivity
  • Other Regulatory Issues

Chapter 9: Analysis of  Market Opportunities

  • Key Drivers
  • Patent Expiration
  • Targeted Nature of ADCs
  • Complexity of ADCs
  • Investor Confidence in Biologics
  • Increased Research on ADC Development
  • Other Factors
  • Key Challenges
  • Manufacturer Strategies

Chapter 10: Company Profiles

Appendix: Abbreviations

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Genentech Inc.
  • Seattle Genetics Inc
  • MORE

The global market for antibody drug conjugates was valued at $1.3 billion in 2016. The market should reach $4.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 25.5% from 2016 to 2021.

North American market for antibody drug conjugates was valued at $588.6 million in 2016. The market should reach $2.0 billion by 2021, growing at a CAGR of 27.2% from 2016 to 2021.

European market for antibody drug conjugates was valued at $395.0 million in 2016. The market should reach $1.2 billion by 2021, growing at a CAGR of 24.1% from 2016 to 2021.

Note: Product cover images may vary from those shown
5 of 6
  • Genentech Inc.
  • Seattle Genetics Inc
  • Takeda Pharmaceuticals Co. Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll